Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oritinib (SH-1028) in Advanced NSCLC
NCT03603262Phase 1Unknown
- Sponsor
- Nanjing Sanhome Pharmaceutical Co., Ltd.
- Start
- Apr 2018
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of rilertinib in non-small cell lung cancer (NSCLC), sponsored by Nanjing Sanhome Pharmaceutical Co., Ltd. Primary endpoints: Maximum Tolerated Dose at 28 days, Dose Limiting Toxicity at 28 days and 3 more. Status: unknown.
02
Drugs
rilertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT03603262.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03603262.